$93.85 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter

Analysts expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to post $93.85 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Ironwood Pharmaceuticals’ earnings. The highest sales estimate is $99.90 million and the lowest is $89.50 million. Ironwood Pharmaceuticals posted sales of $94.21 million during the same quarter last year, which suggests a negative year over year growth rate of 0.4%. The company is expected to issue its next quarterly earnings results on Thursday, February 21st.

According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year sales of $315.28 million for the current year, with estimates ranging from $305.40 million to $342.30 million. For the next fiscal year, analysts expect that the firm will report sales of $393.59 million, with estimates ranging from $341.31 million to $474.70 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.24). The company had revenue of $68.69 million for the quarter, compared to analysts’ expectations of $93.48 million. During the same period in the prior year, the company earned ($0.18) earnings per share. The firm’s revenue was down 20.9% compared to the same quarter last year.

Several equities analysts recently issued reports on IRWD shares. Wedbush reissued a “neutral” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, November 7th. Wells Fargo & Co set a $19.00 price target on shares of Ironwood Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 31st. Morgan Stanley set a $11.00 price target on shares of Ironwood Pharmaceuticals and gave the company a “sell” rating in a report on Wednesday, November 7th. ValuEngine downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 31st. Finally, BTIG Research set a $17.00 price target on shares of Ironwood Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 7th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $16.45.

IRWD stock traded down $1.08 during trading on Friday, hitting $12.72. 2,106,747 shares of the stock traded hands, compared to its average volume of 1,423,737. Ironwood Pharmaceuticals has a one year low of $11.02 and a one year high of $21.20. The company has a market capitalization of $2.13 billion, a P/E ratio of -13.68 and a beta of 1.27.

In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 116,651 shares of the business’s stock in a transaction dated Friday, October 5th. The shares were sold at an average price of $17.53, for a total value of $2,044,892.03. Following the completion of the transaction, the insider now directly owns 70,680 shares of the company’s stock, valued at $1,239,020.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.63% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in IRWD. Pacer Advisors Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the third quarter worth approximately $177,000. Meeder Asset Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth approximately $186,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Ironwood Pharmaceuticals during the third quarter worth approximately $249,000. PNC Financial Services Group Inc. raised its stake in shares of Ironwood Pharmaceuticals by 17,621.9% during the second quarter. PNC Financial Services Group Inc. now owns 17,013 shares of the biotechnology company’s stock worth $325,000 after buying an additional 16,917 shares during the last quarter. Finally, Amalgamated Bank raised its stake in shares of Ironwood Pharmaceuticals by 17.4% during the second quarter. Amalgamated Bank now owns 21,156 shares of the biotechnology company’s stock worth $405,000 after buying an additional 3,142 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Featured Story: Put Option

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply